Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos, 2350, Prédio 12, 4º andar, Porto Alegre, RS, 90035-003, Brazil.
Postgraduate Program in Food, Nutrition, and Health, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Sci Rep. 2020 Nov 12;10(1):19611. doi: 10.1038/s41598-020-76646-6.
Observational and experimental data reinforce the concept that vitamin D is associated with the pathogenesis of arterial hypertension. We investigated the effect of a single dose of 100,000 IU of cholecalciferol, in office blood pressure (BP), and 24-h ambulatory blood pressure monitoring (ABPM) in patients with type 2 diabetes mellitus (DM), hypertension, and hypovitaminosis D. Forty-three patients were randomized to a placebo or cholecalciferol group. BP was assessed by office measurements and 24-h ABPM, before and after intervention. At week 8, a greater decrease in median ABPM values was observed in cholecalciferol supplementation than in the placebo group for systolic 24-h (- 7.5 vs. - 1; P = 0.02), systolic daytime (- 7 vs. - 1; P = 0.007), systolic nighttime (- 7.0 vs. 3; P = 0.009), diastolic 24-h (- 3.5 vs. - 1; P = 0.037), and daytime DBP (- 5 vs. 0; P = 0.01). Office DBP was also reduced after vitamin D supplementation. A single dose of vitamin D improves BP in patients with type 2 diabetes, hypertension, and vitamin D insufficiency, regardless of vitamin D normalization. Vitamin D supplementation could be a valuable tool to treat patients with type 2 DM, hypertension, and hypovitaminosis D.Trial registration: Clinicaltrials.gov NCT02204527.
观察性和实验数据强化了维生素 D 与动脉高血压发病机制相关的概念。我们研究了单次给予 100000IU 胆钙化醇对 2 型糖尿病（DM）、高血压和维生素 D 缺乏症患者的诊室血压（BP）和 24 小时动态血压监测（ABPM）的影响。43 名患者被随机分配至安慰剂或胆钙化醇组。在干预前后通过诊室测量和 24 小时 ABPM 评估 BP。在第 8 周时，与安慰剂组相比，胆钙化醇组的 24 小时收缩压（-7.5 与-1；P=0.02）、日间收缩压（-7 与-1；P=0.007）、夜间收缩压（-7.0 与 3；P=0.009）、24 小时舒张压（-3.5 与-1；P=0.037）和日间舒张压（-5 与 0；P=0.01）的中位数 ABPM 值下降幅度更大。补充胆钙化醇后诊室舒张压也降低。单次剂量的维生素 D 可改善 2 型糖尿病、高血压和维生素 D 不足患者的血压，而与维生素 D 正常化无关。维生素 D 补充可能是治疗 2 型 DM、高血压和维生素 D 缺乏症患者的有效工具。试验注册：Clinicaltrials.gov NCT02204527。
